Peter Attia MDCOVID-19: Current state of affairs, Omicron, and a search for the end game | Peter Attia, M.D.
CHAPTERS
- 0:11 – 13:50
Intro and Omicron Compared to Delta
Peter Attia introduces the episode and his guests, then asks what is known about Omicron versus Delta. Marty Makary cites lab, South African and bedside data pointing to a milder virus, while Zubin Damania notes that prior immunity in South Africa complicates that reading.
- •Makary cites lab data that Omicron replicates about 90% less efficiently in lung cells
- •South African hospital stays were shorter and hospitals were not overrun
- •Damania cautions that high prior immunity in South Africa may explain some of the mildness
- •Discussion of whether Omicron is still COVID or a seasonal coronavirus, and the evolutionary logic of a more transmissible, milder virus
- 13:50 – 17:36
Measuring Immunity: Antibodies vs. B and T Cells
Peter Attia asks whether fixating on circulating antibodies is a mistake because there is no routine test for T cell or memory B cell immunity. Makary and Damania argue antibody titers are a surrogate that has led to a chase for ever-higher levels, and Makary cites UK data on waning protection against symptomatic infection.
- •No commercial test measures T cell immunity or neutralizing antibodies
- •Peter compares antibody levels to judging net worth from a checking account
- •Makary says fixation on titers creates an expectation that vaccines are failing when people test positive
- •UK data show booster protection against symptomatic infection falling within about 10 weeks
- 17:36 – 24:08
What Is the End Game? Policy Questions Since 2019
Peter asks what line in the sand would let the world return to 2019, prompted by being handed a mask and temperature check. Damania frames it as a policy question about how to live, and Makary compares COVID with how we tolerate flu and other respiratory pathogens.
- •Damania says the question is policy-based and has become a tribal identifier
- •Treating cases and antibody levels as the goal implies endless boosters and masking
- •Makary compares daily COVID case counts to the flu, which would create hysteria if tracked the same way
- •Makary says respiratory pathogens will not be eradicated
- 24:08 – 32:47
A Framework: Prevention, Treatment, Supportive Care, and the Toolbox
Peter lays out a three-part framework of preventing infections, treating infections, and supportive care, and compares the spring of 2020 with today. Damania and Makary add lifestyle measures and a back-of-napkin IFR estimate, and Makary stresses that many new therapeutics are not being adopted and that groupthink has hurt medicine.
- •Peter says in under two years we have vaccines, a good sense of which behaviors work, and promising drugs
- •Damania estimates about 1.4 million deaths with no intervention at an IFR of 0.2–0.3%
- •Makary lists fluvoxamine, budesonide and other treatments and says adoption is too slow
- •Makary lists groupthink examples including surface transmission, visitor bans and ignoring natural immunity
- 32:47 – 39:07
Vitamin D, Risk Stratification, and the Research Vacuum
The group discusses the weak evidence for vitamin D, the need to risk-stratify who gets treatments, and why doctors lacked data early on. Makary describes how little NIH funding went to basic COVID questions, which left a vacuum filled by political opinion.
- •Makary says the vitamin D evidence is a retrospective correlation, unlike the randomized data for other treatments
- •Peter prefers sun and exercise to supplementation
- •Damania notes most people recover regardless, which complicates blanket treatment advice
- •Makary says less than 5% of NIH research funding went to COVID and few grants addressed spread or masks
- 39:07 – 46:04
Science vs. Advocacy and the Corruption of Scientific Debate
Peter raises the distinction between science and advocacy and asks whether Fauci is an advocate. Damania and Makary discuss a leaked Francis Collins email, the suppression of dissenting views, and the sidelining of expert advisory committees.
- •Peter says science speaks in uncertainty while advocacy needs certainty, and the line has been blurred
- •Damania reads Collins's email about a takedown of the Great Barrington Declaration as policy advocacy
- •Makary cites Google suppressing lab-leak searches and Kulldorff's removal from an advisory committee
- •Makary says officials bypassed FDA and CDC advisors on boosters for young people
- 46:04 – 58:39
Natural Immunity: What the Evidence Shows
Peter asks what is known about natural immunity and whether it would be unusual for a respiratory virus not to generate it. Makary reviews studies he considers supportive, including the Israeli data, and criticizes two CDC studies as flawed, calling that his opinion.
- •Damania says reinfection with respiratory pathogens is possible but protection against severe disease is usually strong
- •Makary cites SARS and MERS follow-ups, the Cleveland Clinic and Washington University studies
- •Makary describes an Israeli study with an age-adjusted 27-fold greater protection from natural immunity
- •Makary criticizes the two CDC studies as methodologically weak
- •Makary points to 141 studies summarized by Kulldorff
- 58:39 – 1:03:37
Pyrrhic Victory: Eroded Trust and Downstream Harms
Peter calls the pandemic response a Pyrrhic victory for science because of the erosion of trust. Damania and Makary discuss psychological reactance to mandates, harm to children, and costs beyond COVID deaths.
- •Peter says the scientific achievements came at a cost of trust that will matter in the next crisis
- •Damania argues absolutist advocacy backfires by creating reactance
- •Damania lists possible costs: vaccine reluctance, missed screening, substance abuse, mental illness
- •Makary cites a Brown study on cognitive scores in pandemic-born children and a rise in self-harm admissions among young women
- 1:03:37 – 1:18:17
Vaccines, Transmission, and Whether Mandates Fit the Evidence
Peter asks how much vaccines reduce transmission and uses thought experiments to ask whether current mandates fit the evidence. Makary says vaccines mainly reduce severity and shorten contagiousness, and the group argues therapeutics and individual protection shift the policy calculus toward personal choice.
- •Makary cites a Lancet study with equal peak shedding but a shorter contagious window in the vaccinated
- •Peter contrasts a vaccine that reduces severity with one that mainly reduces transmission
- •Damania says decisions have shifted from community-level to individual-level
- •Makary says Paxlovid and molnupiravir trials had no COVID deaths in treatment arms, with Peter noting the trials were small
- •Makary's parachute analogy and his criticism of campus booster mandates
- 1:18:17 – 1:36:09
Vaccine Risks, Peacetime Messaging, and Myocarditis Data
Peter asks why risk discussion of mRNA vaccines is taboo when J&J was paused over very rare events. Damania explains peacetime versus wartime vaccine messaging, and the group reviews myocarditis rates in young males, the Moderna versus Pfizer difference, and uncertainty about long-term outcomes.
- •Damania says peacetime vaccine absolutism has been applied to a wartime situation
- •Makary describes questioning being labeled anti-vaccine and calls VAERS unreliable
- •Myocarditis rates around 1 in 7,600 in young men after the second dose are cited, and Moderna is at least three to four times higher than Pfizer
- •Peter cites a table of myocarditis cases versus ICU admissions and deaths prevented by age and sex
- •Damania says the long-term outcomes of myocarditis cases are not well known
- 1:36:09 – 1:43:45
Boosters, College Mandates, and Policy Bypassing Experts
The conversation turns to booster mandates for college students and the Twitter backlash Peter received. Makary says the WHO has warned against universal boosters and describes the FDA and CDC authorizing boosters after an expert panel voted against them, shortly after a Pfizer press release.
- •Damania says mandates mostly expose low-risk peers, since professors and families can protect themselves
- •Makary cites the WHO statement against universal booster programs and European Moderna restrictions
- •The FDA advisory committee voted 16 to 2 against boosters for everyone over 18, then the agency authorized them without reconvening it
- •Makary says the CDC recommendation for 16- and 17-year-olds came the day after a Pfizer press release
- 1:43:45 – 1:52:20
Fauci, Humility, and Honesty from Officials
Peter and his guests discuss Fauci's repeated claim that attacks on him are attacks on science and the lack of humility from top officials. They use the analogy of doctors admitting mistakes to avoid lawsuits, while still showing some empathy for Fauci's position and arguing that no one person should carry the pandemic response.
- •Peter says lack of humility and doubling down erodes trust, citing gain-of-function denials
- •Damania imagines what an honest apology on gain-of-function would look like
- •Peter says patients sue over arrogance and denial more than over the error itself
- •Damania and Peter express some empathy for Fauci
- •Makary says trust should not rest on one individual and recounts his February warning to the White House
- 1:52:20 – 1:58:50
Is Mass Testing Sensible?
Peter asks whether widespread testing still makes sense now that there are vaccines and therapeutics. The group argues for testing only when it would change management, and Makary criticizes the unsustainable testing burden and the mismatch between official advice and test supply.
- •Peter argues morbidity and mortality matter, not infection counts, and recalls an untested H1N1 illness
- •Makary says asymptomatic positives can cause stress and quarantine with little benefit
- •Peter says to order a test only if the result changes management, and calls testing asymptomatic athletes ridiculous
- •Makary says officials urge mass testing while supplying a fraction of the tests needed
- 1:58:50 – 2:06:22
No Endpoint, Lockdown Costs, and the Real At-Risk Groups
The group asks whether any official has articulated an endpoint and how COVID becomes endemic. Makary separates the roughly 10 to 20 million adults with no immunity from the 250 million with some immunity and cites Australia's reversal, while Damania calls for targeted protection and holistic accounting of costs.
- •Damania says the stated goals kept shifting and no official has described a transition to endemic
- •Makary says a precise group of unvaccinated, non-immune adults and older unboosted people still fill hospitals
- •Makary quotes the Australian prime minister on moving from mandates to responsibility
- •Damania argues for targeted protection over disruptive blunt measures
- •Peter asks about the long-term effect on childhood vaccination rates
- 2:06:22 – 2:25:02
Political Incentives, Tribalism, and the Alt-Middle
The speakers discuss why policymakers retreat to blunt tools, and how political tribes reward polarization. Damania describes an 'alt-middle' synthesis position, and Peter and Damania discuss their own anger at extremes, with Makary warning that polarization would be dangerous in a deadlier future pandemic.
- •Makary says officials retreated to boosters and masks rather than therapeutics when Omicron emerged
- •Damania says politicians play to their base and the travel ban on South Africa was politically expedient
- •Damania argues most people hold a synthesis position when talked through the issues
- •Peter admits his own anger at a pediatrician's masked-family photo and Damania describes how his wife tempers his outrage
- •Makary warns that a pandemic with higher fatality would need diverse opinions and open discussion
- 2:25:02 – 2:33:23
What Parents Can Do and Voices of Reason
Peter asks what parents in restrictive states can do, and Makary recommends demanding endpoints, asking about single doses and natural immunity, and voting. The group then names trusted voices and criteria for trust, including avoiding politically appointed physicians and those who cannot change their minds.
- •Makary says parents should demand clear endpoints and criteria to remove restrictions
- •Makary predicts the language will shift from booster to annual boosting
- •Damania recommends Monica Gandhi, John Mandrola and David Katz
- •Makary names Gandhi, Amesh Adalja and Martin Kulldorff and avoids politically appointed physicians
- •Peter says he distrusts people who never change their opinions
- 2:33:23 – 2:45:29
Strong Convictions, Loosely Held, and Closing
The discussion turns to holding beliefs loosely and the value of updating opinions, using investing and clinical rounds as analogies. Peter wraps up by noting the guests' shared opposition to mandates under current facts, and the episode closes with jokes and membership information.
- •Damania says the one belief beyond question is that you should question your beliefs
- •Peter says the best investors have strong convictions loosely held, while medicine lacks clear outcome feedback
- •Makary says the best clinicians change course with new information and flip-flopping can be appropriate
- •Damania says showing flexibility helps persuasion
- •Peter says they are all anti-mandate given the current facts
